Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be
considered exclusive of other methods of care reasonably directed at obtaining the same results. e
ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer
consideration of each individual patient situation.
Neither IGC, the medical association, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
Abbreviations
CKD, chronic kidney disease; ULT, urate-lowering therapy; XOI, xanthine oxidase inhibitor
Source
Khanna D, FitzGerald JD, Khanna PP, et al. 2012 American College of Rheumatolog y
Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic
erapeutic Approaches to Hyperuricemia. Arthritis Care & Research. 2012;64(10)1431–1446.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2016 All rights reserved
Quality of Evidence
Level Description
A Multiple randomized controlled clinical trials or meta-analyses
B Single randomized trial or nonrandomized studies
C Consensus opinion of experts, case studies or standard-of-care
ACRHYP16013a
